Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results

Posted on: 02 Nov 17

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the third quarter ended September 30, 2017.

“We continue to make important progress toward our goal of bringing GBT440, now known by the non-proprietary name voxelotor, to patients of all ages as a potentially disease-modifying therapeutic option in sickle cell disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “In addition to securing Rare Pediatric Disease designation from the FDA, we’ve continued to share additional voxelotor data in a variety of patient populations at various meetings and as we build momentum toward the end of the year, we look forward to sharing new updates at the upcoming ASH meeting in December including new data from our Phase 2a HOPE-KIDS 1 Study.”

Recent Business Progress

Sickle Cell Disease

  • Announced that the World Health Organization (WHO) approved “voxelotor” as the International Nonproprietary Name (INN) for GBT440, and that the United States Adopted Name Council has adopted “voxelotor” as the United States Adopted Name (USAN) for GBT440. The suffix “elotor” is first-in-class and stands for hemoglobin oxygen affinity modulator.
  • The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to voxelotor for the treatment of sickle cell disease.
  • Hosted the Annual SCD Therapeutics Conference in September, which brought together leading physicians, patient advocates, government agencies, public and private companies and healthcare investment analysts to discuss innovative solutions that could dramatically improve the lives of individuals living with SCD.
  • Presented findings from a case study at the Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference in London, highlighting the effect of voxelotor on markers of anemia and hemolysis (the destruction of red blood cells) in a patient with SCD with the variant HbSC genotype who participated in the Phase 1/2 GBT440-001 study.
  • Presented findings from a single-patient compassionate access case study demonstrating the positive long-term effect of voxelotor in a patient with severe and symptomatic anemia at the Sickle Cell Disease Association of America (SCDAA) 45th Annual National Convention in Atlanta.
  • Received acceptance of a poster for voxelotor on the Improvement of Rheological Properties of Sickle Cell Blood by Increasing Hemoglobin Oxygen Affinity at the upcoming Physiological and Pathophysiological Consequences of Sickle Cell Disease Conference, which will be held on November 6 in Washington D.C.
  • Received acceptance of seven abstracts for presentation at the upcoming 59th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 9-12 in Atlanta. Presentations will include an oral presentation of updated data from the ongoing Phase 2a HOPE-KIDS 1 study, which has been selected for inclusion in the ASH press program.

Hypoxemia Program

  • Discontinued development program of voxelotor for the treatment of idiopathic pulmonary fibrosis, based on results from proof-of-concept studies.


  • Expanded the management team with the promotion of Josh Lehrer, M.D., to senior vice president, clinical development. Since joining the GBT team in 2013, he has overseen the clinical development organization and has led program strategy and execution for voxelotor, bringing it through early-stage studies into a pivotal Phase 3 program in SCD. Prior to GBT, Dr. Lehrer led clinical development programs through proof of concept at Genentech in multiple indications and held key roles in business development and overseeing cardiovascular safety.

Financial Results for the Three Months Ended September 30, 2017
Cash, cash equivalents and marketable securities totaled $259.4 million at September 30, 2017, compared with $197.3 million at December 31, 2016.  We continue to expect our cash, cash equivalents and marketable securities to be sufficient to take us to top-line data in our pivotal HOPE Study.

Net loss for the three months ended September 30, 2017, was $28.6 million compared with $21.0 million for the same period in 2016. Basic and diluted net loss per share for the three months ended September 30, 2017, was $0.66 compared with $0.58 for the same period in 2016.

Research and development (R&D) expenses for the three months ended September 30, 2017, were $21.0 million compared with $15.4 million for the same period in 2016. The increase in R&D expenses is primarily attributable to increased expenses for the Phase 2a HOPE-KIDS 1 Study, the pivotal HOPE Study, two Phase 2a clinical trials in IPF and the Phase 1 Basecamp Study of voxelotor in healthy volunteers under hypoxemic conditions. These increases are partially offset by a decrease in costs related to preclinical pipeline programs, which are primarily due to the discontinuation of the hereditary angioedema, or HAE, program in 2016. We anticipate R&D expenses to increase incrementally quarter over quarter as we increase enrollment in our HOPE study with Part B top-line readout continued to be expected in the first half of 2019.  Total R&D non-cash stock compensation expense incurred for the three months ended September 30, 2017, was $1.6 million compared with $1.1 million for the same period in 2016.

General and administrative (G&A) expenses for the three months ended September 30, 2017, were $8.2 million compared with $5.7 million for the same period in 2016. The increase in G&A expenses is primarily attributable to increased professional fees and employee-related costs associated with the growth of the Company's operations. Total G&A non-cash stock compensation expense incurred in the three months ended September 30, 2017, was $2.1 million, compared with $2.0 million for the same period in 2016.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit: and follow the company on Twitter: @GBT_News.

Forward-Looking Statements
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the therapeutic potential and safety profile of voxelotor (previously called GBT440), our ability to implement our clinical development plans for voxelotor, our ability to generate and report data from our ongoing and potential future studies of voxelotor, regulatory review and actions relating to voxelotor, our ability to adequately obtain and protect our intellectual property rights, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that results of clinical trials may be subject to differing interpretations, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, that drug-related adverse events may be observed in clinical development, and that data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Condensed Consolidated Statements of Operations 
(In thousands, except share and per share amounts) 
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2017 2016 2017 2016
Operating expenses:       
Research and development$20,952  $15,413  $56,513  $41,256 
General and administrative8,228  5,731  20,817  14,412 
Total operating expenses29,180  21,144  77,330  55,668 
Loss from operations(29,180) (21,144) (77,330) (55,668)
Other income (expense):           
Interest income, net727  159  1,856  407 
Other expenses, net(104)   (298)  
Total other income, net623  159  1,558  407 
Net loss$(28,557) $(20,985) $(75,772) $(55,261)
Basic and diluted net loss per common share$(0.66) $(0.58) $(1.81) $(1.72)
Weighted-average number of shares used in
computing basic and diluted net loss per
common share
43,259,145  36,353,958  41,832,273  32,074,779 

Condensed Consolidated Balance Sheets
(In thousands)
  September 30, 2017 December 31, 2016
  (Unaudited)  (1)
Current assets:    
Cash and cash equivalents $84,149  $92,072 
Short-term marketable securities  135,206   55,202 
Prepaid expenses and other current assets  10,415   2,495 
Total current assets  229,770   149,769 
Long-term marketable securities  40,073   50,058 
Other assets  14,215   2,560 
Total assets $284,058   $202,387 
Liabilities and Stockholders’ Equity    
Current liabilities $  16,357  $  15,515 
Other liabilities, noncurrent  9,434   563 
Total liabilities  25,791   16,078 
Total stockholders’ equity  258,267   186,309 
Total liabilities and stockholders’ equity $284,058  $202,387 
(1) Derived from the audited financial statements, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 13, 2017.

Contact Information:
Myesha Lacy (investors)

Julie Normart (media)
Pure Communications


Last updated on: 03/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.